My experience of rotation
Release time:
2022-11-01
Starting from February # this year, the office staff of the marketing department of Huang Ping Jianfeng Cement Company will rotate their posts, cross-learn, motivate employees and improve their skills, so as to cultivate compound talents who can stand alone.
6# May29 , after the administrative class of that day, I will embark on the long-awaited one-month post-taking of the consignor. In order to ensure that I can be competent for the job of the consignor, before that, I specially used my spare time at work to learn from the consignor's practical operation for a few days and mastered the daily basic operations, such as placing orders manually, handling tare weight abnormalities, handling electronic tags, cement numbering, etc. But when things come to an end, my heart is still excited and uneasy. The excitement is that you can have a different work experience; the tension is that you are afraid that you will not be able to deal with emergencies in the middle of the night, causing logistics paralysis. 30
, after going to work, I will finish the handover with my colleagues, which means that I will finish the delivery work independently in the next24 hours. In the early stage of study, not all the work can be done in practice, and there are colleagues on the side while doing practical exercises, so I naturally feel more confident.
Before, I was in a back office position. I didn't deal with drivers very much. Although I just changed jobs, I still deeply realized that it is not easy to deal with drivers with different personalities."Master, I'm sorry! Today is my first day at work, I am not very skilled, a little slow, please wait a minute! " is a passage that my first class often talks about. Fortunately, most of the drivers I met on that day were very patient and understood me. They also encouraged me "It's okay, don't make mistakes, it doesn't matter to slow down, it's the first time, just do it a few more times! " Of course, you will also meet a driver who is very anxious. He will not give you a good look. After you have dealt with the problem for him, you will mercilessly say "Why did you come to work if you did not learn well? Wasting my time. " Turned and slammed the door and went away ... As a service window, facing different faces every day, effectively dealing with customers and drivers with a smile. At the same time, you should also learn to adjust your emotions all the time. When you meet a driver who understands and tolerates you, your heart is really warm. When you meet a driver who speaks hard, you should learn to digest yourself, learn to reflect on yourself and improve continuously. At the same time, we should also learn to bear physical fatigue and deal with problems in the middle of the night. In the face of emotional drivers, we should first appease the drivers and effectively solve the problems.
Time is fleeting, and a tense and fulfilling month has passed. In this month, I worked and studied, and constantly honed my working ability in practice, and also cultivated my ability to adapt to the new environment. This month, although I did not have vigorous results, but also experienced a different period of training, but also understand the shipper this position is not easy and important.(Long Liwei)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31